# Eli Lilly and Company

- Category: Pharmaceuticals & Life Sciences
- Address: Lilly Corporate Center, Indianapolis, IN 46285
- Phone: +1 317-276-2000
- Website: https://www.lilly.com
- Last updated: 2026-11-15
- Source page: https://professionalbusinessdirectory.com/places/eli-lilly-and-company/

## Profile

Eli Lilly and Company discovers, develops, manufactures and markets human pharmaceutical products, which it sells in about 90 countries. Its Form 10-K for the year ended December 31, 2025 lists the principal executive offices at Lilly Corporate Center, Indianapolis, Indiana 46285, and reports 2025 revenue of $65,179 million.

## Identity

- Legal name: Eli Lilly and Company

- Ticker and exchange: LLY, New York Stock Exchange

- SEC Central Index Key (CIK): 0000059478. Commission file number: 001-06351

- State of incorporation: Indiana. The 10-K says the company was incorporated in 1901 to succeed a drug manufacturing business founded in Indianapolis in 1876.

- Fiscal year end: December 31

- SEC industry code: 2834, pharmaceutical preparations

- Directory category: Pharmaceuticals & Life Sciences

## Products by therapeutic area

The 10-K reports one business segment, human pharmaceutical products, and groups its products into four therapeutic areas:

- Cardiometabolic Health: Mounjaro, Zepbound, Trulicity, Jardiance, Basaglar, Humalog and Humulin.

- Oncology: Verzenio, Cyramza, Erbitux, Inluriyo, Jaypirca, Retevmo and Tyvyt.

- Immunology: Taltz, Olumiant, Omvoh and Ebglyss.

- Neuroscience: Emgality and Kisunla.

Indications for each product are listed in Item 1 of the 10-K. This listing does not describe treatments.

## 2025 revenue

Revenue was $65,179 million in 2025, up 45% from $45,043 million in 2024. The U.S. accounted for $43,481 million and markets outside the U.S. for $21,698 million. Three products are itemized in the 10-K's revenue table: Mounjaro $22,965 million, Zepbound $13,542 million and Verzenio $5,723 million. Research and development expense was $13,337 million and net income was $20,640 million.

## Workforce and facilities

At the end of 2025 Lilly employed about 50,000 people, including about 27,000 outside the U.S. and about 12,000 in research and development. Item 2 states that the principal domestic and international executive offices are in Indianapolis. Major production sites are in Indiana, North Carolina, Puerto Rico and Wisconsin in the U.S., and in Ireland, France, Spain, Italy, China and Japan abroad. Research and development facilities are owned in Indiana and leased in California, Massachusetts, Colorado and New York.

## How to verify this company yourself

- [SEC EDGAR filing list for Eli Lilly & Co (CIK 0000059478)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478&type=10-K&dateb=&owner=include&count=10)

- [Form 10-K for the fiscal year ended December 31, 2025](https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm) (filed February 12, 2026): cover page, Item 1, Item 2

- [Lilly Investors](https://investor.lilly.com/) (news releases, results, events)

- [Lilly contact page](https://www.lilly.com/about/contact) (patients, health care providers, media)

- [Lilly Medical contact page](https://medical.lilly.com/us/products/contact) (medical information requests, adverse event and product complaint reports)

## Location and contact

- Principal executive offices (Form 10-K cover): Lilly Corporate Center, Indianapolis, Indiana 46285. The cover does not print a street number.

- Corporate telephone (Form 10-K cover): [+1 317-276-2000](tel:+13172762000)

- Investors (contact line in Lilly's January 21, 2026 news release): [+1 317-617-0983](tel:+13176170983)

- Lilly Support Services, U.S. (Lilly investor site and contact page): [+1 800-545-5979](tel:+18005455979), for questions about Lilly medicines

- Website (stated in the 10-K): [lilly.com](https://www.lilly.com)

Last verified: November 6, 2026. Sources: Eli Lilly and Company Form 10-K for fiscal 2025 and SEC EDGAR company record; investor.lilly.com; Lilly news release of January 21, 2026; lilly.com/about/contact; medical.lilly.com contact page.
Directory listing. Not medical advice; in an emergency call 911. Not investment advice and not a product review. Financial figures are copied from the cited filing and are not forecasts.
Listing type: Editorial. Not claimed by the company. Not sponsored. [Send a correction](https://professionalbusinessdirectory.com/contact/).

---
Published by Professional Business Directory (https://professionalbusinessdirectory.com/). Editorial process: https://professionalbusinessdirectory.com/editorial-process/
